Zymeworks (ZYME) Net Equity Issued and Repurchased (2022 - 2023)
Zymeworks (ZYME) posted Net Equity Issued and Repurchased of $26.2 million for Q2 2023, up 14203.76% sequentially from -$186000.0 in Q2 2022, and up 14203.76% YoY from N/an in Q2 2022.
Powered by 
Analysis
Zymeworks (ZYME) Net Equity Issued and Repurchased (2022 - 2023) Analysis & Trends
Zymeworks has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $26.2 million in Q2 2023.
- Quarterly Net Equity Issued and Repurchased rose 14203.76% year-over-year to $26.2 million in Q2 2023, while the trailing twelve-month figure through Sep 2024 was $26.2 million (changed 0.0% YoY) and the FY2023 annual result came in at $26.2 million, down 75.6% from the prior year.
- Net Equity Issued and Repurchased climbed to $26.2 million in Q2 2023 per ZYME's latest filing, from -$186000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $107.7 million in Q1 2022 and troughed at -$186000.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 26.23 Mn |
| Jun 30, 2022 | -186,000.00 |
| Mar 31, 2022 | 107.72 Mn |